Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Grant Number: R34HL122558
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
This PHASE2 trial investigates Lung Diseases, Interstitial and Scleroderma and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Oct 2019 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Northwestern University
For direct contact, visit the study record on ClinicalTrials.gov .